Table Graph
      published meta-analysis   sensitivity analysis   studies

Comirnaty (tozinameran - Pfizer/BIONTECH) in COVID-19 prophylaxis (excluding children) - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 6 months symptomatic COVIDdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.09 [0.07; 0.11] 0.09[0.07; 0.11]BNT162b2 phase 3 (C4591001, Polack), 202010%46,077NAnot evaluable confirmed Covid-19, from 1st dosedetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.18 [0.13; 0.25] Tang, 2021 0.16 [0.10; 0.25] 0.17[0.13; 0.22]BNT162b2 phase 3 (C4591001, Polack), 2020, Tang, 202120%47,789lownot evaluable deathsdetailed resultsBernal, 0 0.31 [0.14; 0.69] BNT162b2 phase 3 (C4591001, Polack), 2020 0.50 [0.09; 2.73] Goldberg, 2021 0.06 [0.05; 0.07] Haas, 2021 0.03 [0.03; 0.04] 0.09[0.05; 0.19]Bernal, 0, BNT162b2 phase 3 (C4591001, Polack), 2020, Goldberg, 2021, Haas, 2021494%43,252NAnot evaluable vaccine efficacy from randomization (ITT)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.18 [0.13; 0.25] 0.18[0.13; 0.25]BNT162b2 phase 3 (C4591001, Polack), 202010%42,572NAnot evaluable confirmed COVID (any severity)detailed resultsBernal (PHE, 19th February 2021), 2021 0.39 [0.31; 0.49] Bjork, 2021 0.14 [0.06; 0.30] Butt, 2021 0.04 [0.03; 0.05] England (Andrews), 2021 0.51 [0.35; 0.76] Heymann, 2021 0.11 [0.06; 0.19] South Africa (Discovery Health, Collie), 2021 0.50 [0.38; 0.65] Tartof, 2021 0.27 [0.26; 0.28] 0.21[0.10; 0.42]Bernal (PHE, 19th February 2021), 2021, Bjork, 2021, Butt, 2021, England (Andrews), 2021, Heymann, 2021, South Africa (Discovery Health, Collie), 2021, Tartof, 2021799%240,168NAnot evaluable hospitalizationdetailed resultsDagan, 2021 0.13 [0.00; Infinity] Goldberg, 2021 0.06 [0.05; 0.06] Haas, 2021 0.03 [0.02; 0.03] Mayo Clinic (Puranik), 2021 0.25 [0.07; 0.88] South Africa (Discovery Health, Collie), 2021 0.30 [0.24; 0.38] Tartof, 2021 0.10 [0.09; 0.12] Tenforde, 2021 0.16 [0.12; 0.22] 0.11[0.05; 0.20]Dagan, 2021, Goldberg, 2021, Haas, 2021, Mayo Clinic (Puranik), 2021, South Africa (Discovery Health, Collie), 2021, Tartof, 2021, Tenforde, 2021799%1,243,040lownot evaluable symptomatic Covid-19detailed resultsAndrejko, 2021 0.13 [0.05; 0.32] Angel, 2021 0.03 [0.01; 0.07] BNT162b2 phase 3 (C4591001, Polack), 2020 0.05 [0.02; 0.10] Canada (Nasreen), 2021 0.13 [0.05; 0.35] Chung, 2021 0.09 [0.07; 0.12] Dagan, 2021 0.06 [0.02; 0.15] England (Andrews), 2021 0.51 [0.35; 0.76] Haas, 2021 0.03 [0.03; 0.03] Mayo Clinic (Puranik), 2021 0.58 [0.38; 0.88] Nanduri, 2021 0.48 [0.44; 0.52] Oxford (Pouwels), 2021 0.16 [0.14; 0.18] Public Health England, May 16, 2021 (Bernal), 2021 0.12 [0.10; 0.15] Qatar (Tang), 2021 0.47 [0.39; 0.56] Scotland delta (Sheikh), 2021 0.17 [0.13; 0.22] South Africa (Discovery Health, Collie), 2021 0.50 [0.38; 0.65] Tang, 2021 0.00 [0.00; 0.05] 0.14[0.07; 0.27]Andrejko, 2021, Angel, 2021, BNT162b2 phase 3 (C4591001, Polack), 2020, Canada (Nasreen), 2021, Chung, 2021, Dagan, 2021, England (Andrews), 2021, Haas, 2021, Mayo Clinic (Puranik), 2021, Nanduri, 2021, Oxford (Pouwels), 2021, Public Health England, May 16, 2021 (Bernal), 2021, Qatar (Tang), 2021, Scotland delta (Sheikh), 2021, South Africa (Discovery Health, Collie), 2021, Tang, 20211699%1,886,061lowlow 6 months severe COVID-19detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.03 [0.00; 0.46] 0.03[0.00; 0.46]BNT162b2 phase 3 (C4591001, Polack), 202010%NAnot evaluable asymptomatic COVID casedetailed resultsAngel, 2021 0.14 [0.07; 0.29] Haas, 2021 0.09 [0.08; 0.09] Tang, 2021 0.28 [0.18; 0.43] Weekes, 2021 0.25 [0.09; 0.72] 0.16[0.08; 0.35]Angel, 2021, Haas, 2021, Tang, 2021, Weekes, 2021491%16,732NAnot evaluable infection (PCR positive symptomatic or not)detailed resultsAmit, 2021 0.25 [0.19; 0.33] Bjork, 2021 0.14 [0.06; 0.30] Cavanaugh, 2021 0.38 [0.19; 0.76] Dagan, 2021 0.08 [0.05; 0.12] Goldberg, 2021 0.07 [0.07; 0.07] Heymann, 2021 0.11 [0.06; 0.19] Oxford (Pouwels), 2021 0.20 [0.17; 0.23] Scotland delta (Sheikh), 2021 0.21 [0.18; 0.25] SIREN (HW england), 2021 0.15 [0.06; 0.38] Tang, 2021 0.21 [0.15; 0.29] Weekes, 2021 0.23 [0.11; 0.49] 0.16[0.10; 0.26]Amit, 2021, Bjork, 2021, Cavanaugh, 2021, Dagan, 2021, Goldberg, 2021, Heymann, 2021, Oxford (Pouwels), 2021, Scotland delta (Sheikh), 2021, SIREN (HW england), 2021, Tang, 2021, Weekes, 20211198%1,374,863lowcritical severe COVID-19 occurrencedetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.25 [0.01; 5.62] Canada (Nasreen), 2021 0.05 [0.03; 0.08] Dagan, 2021 0.08 [0.00; Infinity] Goldberg, 2021 0.06 [0.05; 0.06] Grannis, 2021 0.20 [0.15; 0.27] Haas, 2021 0.03 [0.02; 0.03] Mayo Clinic (Puranik), 2021 0.25 [0.07; 0.88] Qatar (Tang), 2021 0.10 [0.02; 0.47] Tenforde, 2021 0.16 [0.12; 0.22] 0.09[0.05; 0.17]BNT162b2 phase 3 (C4591001, Polack), 2020, Canada (Nasreen), 2021, Dagan, 2021, Goldberg, 2021, Grannis, 2021, Haas, 2021, Mayo Clinic (Puranik), 2021, Qatar (Tang), 2021, Tenforde, 2021997%1,296,930moderatenot evaluable transmission (symptomatic confirmed COVID19)detailed resultsHarris, 2021 0.54 [0.47; 0.62] Public Health England (Harris), 2021 0.51 [0.44; 0.59] 0.53[0.48; 0.58]Harris, 2021, Public Health England (Harris), 202120%seriousnot evaluable vaccine efficacy after dose 1 (and before dose 2)detailed resultsAmit, 2021 0.15 [0.08; 0.29] BNT162b2 phase 3 (C4591001, Polack), 2020 0.48 [0.32; 0.71] Chodcik, 2021 0.49 [0.22; 1.07] Scotland cohort, 0 0.15 [0.09; 0.24] SIREN (HW england), 2021 0.30 [0.17; 0.52] Tang, 2021 0.42 [0.26; 0.69] 0.29[0.19; 0.46]Amit, 2021, BNT162b2 phase 3 (C4591001, Polack), 2020, Chodcik, 2021, Scotland cohort, 0, SIREN (HW england), 2021, Tang, 2021675%1,617,658lownot evaluable cerebrovascular thromboembolic eventsdetailed resultsBarda, 2021 0.84 [0.55; 1.29] 0.84[0.55; 1.29]Barda, 202110%NAnot evaluable related AE (TRAE)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 4.91 [4.58; 5.26] 4.91[4.58; 5.26]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable related SAE (TRSAE)detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 8.00 [0.42; 151.43] 8.00[0.42; 151.43]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable serious adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.14 [0.88; 1.47] 1.14[0.88; 1.47]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable acute kidney injury detailed resultsBarda, 2021 0.44 [0.25; 0.78] 0.44[0.25; 0.78]Barda, 202110%NAnot evaluable adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 2.62 [2.49; 2.76] 2.62[2.49; 2.76]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable Anemia detailed resultsBarda, 2021 0.79 [0.67; 0.93] 0.79[0.67; 0.93]Barda, 202110%NAnot evaluable arrhythmiadetailed resultsBarda, 2021 0.89 [0.75; 1.06] 0.89[0.75; 1.06]Barda, 202110%NAnot evaluable Arthritis or arthropathy detailed resultsBarda, 2021 0.95 [0.66; 1.36] 0.95[0.66; 1.36]Barda, 202110%NAnot evaluable convulsions/seizures detailed resultsBarda, 2021 0.99 [0.61; 1.61] Klein, 2021 1.04 [0.84; 1.29] 1.03[0.85; 1.26]Barda, 2021, Klein, 202120%150criticalnot evaluable deep vein thrombosisdetailed resultsBarda, 2021 0.87 [0.55; 1.39] 0.87[0.55; 1.39]Barda, 202110%NAnot evaluable disseminated intravascular coagulation detailed resultsKlein, 2021 0.70 [0.39; 1.27] 0.70[0.39; 1.27]Klein, 202110%25NAnot evaluable Guillain-Barré syndrome detailed resultsKlein, 2021 0.70 [0.22; 2.27] Li X, 2022 0.79 [0.33; 1.90] Patone, 2021 0.86 [0.54; 1.36] 0.83[0.56; 1.22]Klein, 2021, Li X, 2022, Patone, 202130%6NAnot evaluable Herpes simplex infection detailed resultsBarda, 2021 1.13 [0.94; 1.36] 1.13[0.94; 1.36]Barda, 202110%NAnot evaluable herpes zoster infection detailed resultsBarda, 2021 1.43 [1.19; 1.72] Shasha, 2021 1.07 [0.85; 1.35] 1.25[0.94; 1.66]Barda, 2021, Shasha, 2021273%moderatenot evaluable immune thrombocytopenia detailed resultsKlein, 2021 1.12 [0.64; 1.95] 1.12[0.64; 1.95]Klein, 202110%23NAnot evaluable intracranial hemorrhage detailed resultsBarda, 2021 0.48 [0.23; 1.01] Patone, 2021 1.24 [1.07; 1.43] 0.83[0.33; 2.08]Barda, 2021, Patone, 2021283%moderatenot evaluable ischemic strokedetailed resultsEPI-PHARE, 2021 0.99 [0.84; 1.16] Klein, 2021 0.97 [0.87; 1.08] 0.98[0.89; 1.07]EPI-PHARE, 2021, Klein, 202120%650criticalnot evaluable life-threatening SAEdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 0.91 [0.51; 1.65] 0.91[0.51; 1.65]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable Myocardial infarction detailed resultsBarda, 2021 1.07 [0.73; 1.57] EPI-PHARE, 2021 1.07 [0.88; 1.31] Klein, 2021 1.02 [0.89; 1.17] 1.04[0.93; 1.16]Barda, 2021, EPI-PHARE, 2021, Klein, 202130%375criticalnot evaluable myocarditisdetailed resultsBarda, 2021 3.24 [1.14; 9.18] Husby (pfizer), 2021 1.34 [0.90; 2.00] Klein, 2021 1.18 [0.78; 1.78] 1.40[0.96; 2.04]Barda, 2021, Husby (pfizer), 2021, Klein, 2021336%39moderatenot evaluable neutropenia detailed resultsBarda, 2021 0.87 [0.46; 1.65] 0.87[0.46; 1.65]Barda, 202110%NAnot evaluable paresthesia detailed resultsBarda, 2021 1.12 [1.00; 1.26] Shasha, 2021 1.22 [1.11; 1.34] 1.18[1.09; 1.28]Barda, 2021, Shasha, 2021220%moderatenot evaluable pericarditis detailed resultsBarda, 2021 1.27 [0.69; 2.34] Klein, 2021 1.18 [0.78; 1.78] 1.21[0.86; 1.70]Barda, 2021, Klein, 202120%39criticalnot evaluable pulmonary embolismdetailed resultsBarda, 2021 0.56 [0.24; 1.31] EPI-PHARE, 2021 1.15 [0.90; 1.46] Klein, 2021 1.01 [0.86; 1.19] 1.03[0.86; 1.24]Barda, 2021, EPI-PHARE, 2021, Klein, 2021329%290criticalnot evaluable severe adverse eventsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.74 [1.41; 2.14] 1.74[1.41; 2.14]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable thrombocytopenia detailed resultsBarda, 2021 0.94 [0.66; 1.33] 0.94[0.66; 1.33]Barda, 202110%NAnot evaluable Transverse myelitis detailed resultsKlein, 2021 1.45 [0.07; 31.68] 1.45[0.07; 31.68]Klein, 202110%1NAnot evaluable uveitis detailed resultsBarda, 2021 1.27 [0.64; 2.52] 1.27[0.64; 2.52]Barda, 202110%NAnot evaluable venous thromboembolism detailed resultsKlein, 2021 1.16 [1.00; 1.34] 1.16[1.00; 1.34]Klein, 202110%327NAnot evaluable VTE with thrombocytopeniadetailed resultsKlein, 2021 0.86 [0.58; 1.27] 0.86[0.58; 1.27]Klein, 202110%53NAnot evaluable cerebral venous sinus thrombosis (CVST)detailed resultsKlein, 2021 1.55 [0.33; 7.28] McMurry, 2021 0.33 [0.01; 8.42] Pawlowski, 2021 1.50 [0.30; 7.55] 1.30[0.45; 3.73]Klein, 2021, McMurry, 2021, Pawlowski, 202130%3moderatenot evaluable appendicitisdetailed resultsBarda, 2021 1.40 [1.00; 1.97] BNT162b2 phase 3 (C4591001, Polack), 2020 2.00 [0.60; 6.65] Klein, 2021 0.82 [0.73; 0.93] 1.14[0.69; 1.86]Barda, 2021, BNT162b2 phase 3 (C4591001, Polack), 2020, Klein, 2021381%43,939criticalnot evaluable Bell's palsydetailed resultsBarda, 2021 1.32 [0.93; 1.88] BNT162b2 phase 3 (C4591001, Polack), 2020 7.99 [0.42; 151.24] Klein, 2021 1.00 [0.86; 1.17] Li X, 2022 0.83 [0.62; 1.11] McMurry, 2021 0.40 [0.21; 0.78] Patone, 2021 1.06 [0.90; 1.25] Shasha, 2021 0.96 [0.54; 1.70] Shemer, 2021 0.84 [0.37; 1.90] Shibli, 2021 1.36 [1.14; 1.62] Wan, 2021 1.75 [0.89; 3.48] 1.05[0.88; 1.26]Barda, 2021, BNT162b2 phase 3 (C4591001, Polack), 2020, Klein, 2021, Li X, 2022, McMurry, 2021, Patone, 2021, Shasha, 2021, Shemer, 2021, Shibli, 2021, Wan, 20211064%37,887lowlow hypersensitivity, all termsdetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 2.17 [0.82; 5.71] 2.17[0.82; 5.71]BNT162b2 phase 3 (C4591001, Polack), 202010%43,252NAnot evaluable immediate allergic reactiondetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.00 [0.02; 50.42] 1.00[0.02; 50.42]BNT162b2 phase 3 (C4591001, Polack), 202010%43,448NAnot evaluable lymphadenopathy, anydetailed resultsBarda, 2021 2.43 [2.09; 2.83] BNT162b2 phase 3 (C4591001, Polack), 2020 10.69 [4.63; 24.69] 4.80[1.13; 20.41]Barda, 2021, BNT162b2 phase 3 (C4591001, Polack), 2020291%37,586seriousnot evaluable musculoskeletal and connective tissue disorders, anydetailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 3.65 [3.26; 4.09] 3.65[3.26; 4.09]BNT162b2 phase 3 (C4591001, Polack), 202010%37,586NAnot evaluable myelitisdetailed resultsLi X, 2022 0.77 [0.40; 1.48] Patone, 2021 1.14 [0.86; 1.51] 1.05[0.77; 1.43]Li X, 2022, Patone, 2021214%NAnot evaluable local adverse reaction, any, dose 1detailed resultsOut of scaleBNT162b2 phase 3 (C4591001, Polack), 2020 24.90 [22.13; 28.03] 24.90[22.13; 28.03]BNT162b2 phase 3 (C4591001, Polack), 202010%8,183NAnot evaluable local adverse reaction, any, dose 2detailed resultsOut of scaleBNT162b2 phase 3 (C4591001, Polack), 2020 23.04 [20.30; 26.15] 23.04[20.30; 26.15]BNT162b2 phase 3 (C4591001, Polack), 202010%7,507NAnot evaluable systemic adverse reaction, any, dose 1detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 1.63 [1.50; 1.78] 1.63[1.50; 1.78]BNT162b2 phase 3 (C4591001, Polack), 202010%8,183NAnot evaluable systemic adverse reaction, any, dose 2detailed resultsBNT162b2 phase 3 (C4591001, Polack), 2020 4.55 [4.13; 5.01] 4.55[4.13; 5.01]BNT162b2 phase 3 (C4591001, Polack), 202010%7,507NAnot evaluable serologic response (seroconversion)detailed resultsGrupper, 2021 0.01 [0.00; 0.21] Monin, 2021 0.78 [0.02; 25.26] 0.09[0.00; 5.02]Grupper, 2021, Monin, 2021270%192NAnot evaluable0.020.01.0relative treatment effectwww.metaEvidence.org2024-06-01 02:49 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 89 - treatments: 758 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons